menu
    • menu
    [{"orgOrder":0,"company":"SolasCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"SolasCure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Undisclosed"},{"orgOrder":0,"company":"SolasCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"SolasCure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Undisclosed"},{"orgOrder":0,"company":"SolasCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"SolasCure \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SolasCure \/ Undisclosed"},{"orgOrder":0,"company":"SolasCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"SolasCure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by SolasCure

    Menu

    SolasCure

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SolasCure

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SolasCure

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarumase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SolasCure Gets FDA Fast Track for Aurase Wound Gel for Calciphylaxis Ulcers

                            Details : Aurase Wound Gel contains Tarumase, a clone of the key enzyme in maggot saliva that breaks down fibrin, elastin and collagen in wounds. It is being investigated for calciphylaxis ulcers.

                            Product Name : Aurase Wound Gel

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            June 16, 2025

                            Lead Product(s) : Tarumase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SolasCure

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SolasCure

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarumase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SolasCure Enrols First Patient in Phase 2 Trial for Aurase Wound Gel

                            Details : Aurase Wound Gel is a hydrogel releasing Tarumase, a recombinant enzyme that selectively targets fibrin, collagen & elastin in wounds to promote healing through debridement.

                            Product Name : Aurase Wound Gel

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : Tarumase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SolasCure

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SolasCure

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarumase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SolasCure Demonstrates Proof-of-Concept in Phase lla Safety Trial of Aurase Wound Gel

                            Details : Aurase is an enzyme analogue large molecule drug candidate, which is currently being evaluated for the treatment of patients suffering from chronic venous leg ulcer.

                            Product Name : Aurase

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            December 12, 2023

                            Lead Product(s) : Tarumase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SolasCure

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SolasCure

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tarumase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial Enzyme Application Targeting Venous Leg Ulcers

                            Details : Aurase Wound gel (Tarumase) is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leg Ulcer.

                            Product Name : Aurase Wound gel

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 09, 2021

                            Lead Product(s) : Tarumase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth